Deka Bank Deutsche Girozentrale I Mab Transaction History

Deka Bank Deutsche Girozentrale

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$8.27 - $18.43 $26,877 - $59,897	-3,250 Closed	0 $0
Q1 2022 Apr 28, 2022	SELL	$12.54 - $46.93 $242,912 - $909,081	-19,371 Reduced 85.63%	3,250 $323,000
Q4 2021 Feb 02, 2022	BUY	$45.28 - $74.5 $83,360 - $137,154	1,841 Added 8.86%	22,621 $1.03 Million
Q3 2021 Oct 22, 2021	BUY	$57.18 - $84.43 $793,429 - $1.17 Million	13,876 Added 200.98%	20,780 $1.47 Million
Q2 2021 Aug 05, 2021	BUY	$47.86 - $83.95 $100,697 - $176,630	2,104 Added 43.83%	6,904 $552,000
Q4 2020 Mar 12, 2021	BUY	$32.94 - $47.15 $158,112 - $226,320	4,800 New	4,800 $195,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $80.6M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.